Modulation of Gene Expression Using Zinc Finger-Based Artificial Transcription Factors

  • Sabine Stolzenburg
  • Alan Bilsland
  • W. Nicol Keith
  • Marianne G. Rots
Part of the Methods in Molecular Biology book series (MIMB, volume 649)


Artificial transcription factors (ATFs) consist of a transcriptional effector domain fused to a DNA-binding domain such as an engineered zinc finger protein (ZFP). Depending on the effector domain, ATFs can up- or downregulate gene expression and thus represent powerful tools in biomedical research and allow novel approaches in clinical practice. Here, we describe the construction of ATFs directed against the promoter of the epithelial cell adhesion molecule and against the promoter of the RNA component of telomerase. Methods to assess DNA binding of the engineered ZFP as well as to determine and improve the cellular effect of ATFs on (endogenous) promoter activity are described.

Key words

Transient gene expression modulation VP64 Krüppel-associated box (KRAB) artificial transcription factors valproic acid 


  1. 1.
    Visser, A.E., Verschure, P.J., Gommans, W.M., Haisma, H.J., and Rots, M.G. (2006) Step into the groove: engineered transcription factors as modulators of gene expression. Adv Genet. 56, 131–161.PubMedCrossRefGoogle Scholar
  2. 2.
    Lu, Y., Tian, C., Danialou, G., Gilbert, R., Petrof, B.J., Karpati, G., and Nalbantoglu, J. (2008) Targeting artificial transcription factors to the utrophin A promoter: effects on dystrophic pathology and muscle function. J Biol Chem. 283, 34720–34727.PubMedCrossRefGoogle Scholar
  3. 3.
    Beltran, A., Parikh, S., Liu, Y., Cuevas, B.D., Johnson, G.L., Futscher, B.W., and Blancafort, P. (2007) Re-activation of a dormant tumor suppressor gene maspin by designed transcription factors. Oncogene. 26, 2791–2798.PubMedCrossRefGoogle Scholar
  4. 4.
    Kang, Y.A., Shin, H.C., Yoo, J.Y., Kim, J.H., Kim, J.S., and Yun, C.O. (2008) Novel cancer antiangiotherapy using the VEGF promoter-targeted artificial zinc-finger protein and oncolytic adenovirus. Mol Ther. 16, 1033–1040.PubMedCrossRefGoogle Scholar
  5. 5.
    Sera, T. (2009) Zinc-finger-based artificial transcription factors and their applications. Adv Drug Deliv Rev. 61, 513–526.PubMedCrossRefGoogle Scholar
  6. 6.
    Verschure, P.J., Visser, A.E., and Rots, M.G. (2006) Step out of the groove: epigenetic gene control systems and engineered transcription factors. Adv Genet. 56, 163–204.PubMedCrossRefGoogle Scholar
  7. 7.
    Beltran, A.S., Sun, X., Lizardi, P.M., and Blancafort, P. (2008) Reprogramming epigenetic silencing: artificial transcription factors synergize with chromatin remodeling drugs to reactivate the tumor suppressor mammary serine protease inhibitor. Mol Cancer Ther. 7, 1080–1090.PubMedCrossRefGoogle Scholar
  8. 8.
    Carroll, D., Morton, J.J., Beumer, K.J., and Segal, D.J. (2006) Design, construction and in vitro testing of zinc finger nucleases. Nat Protoc. 1, 1329–1341.PubMedCrossRefGoogle Scholar
  9. 9.
    Gommans, W.M., McLaughlin, P.M., Lindhout, B.I., Segal, D.J., Wiegman, D.J., Haisma, H.J., van der Zaal, B.J., and Rots, M.G. (2007) Engineering zinc finger protein transcription factors to downregulate the epithelial glycoprotein-2 promoter as a novel anti-cancer treatment. Mol Carcinog. 46, 391–401.PubMedCrossRefGoogle Scholar
  10. 10.
    Zhao, J.Q., Hoare, S.F., McFarlane, R., Muir, S., Parkinson, E.K., Black, D.M., and Keith, W.N. (1998) Cloning and characterization of human and mouse telomerase RNA gene promoter sequences. Oncogene. 16, 1345–1350.PubMedCrossRefGoogle Scholar
  11. 11.
    Shay, J.W. and Keith, W.N. (2008) Targeting telomerase for cancer therapeutics. Br J Cancer. 98, 677–683.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Sabine Stolzenburg
    • 1
  • Alan Bilsland
    • 2
  • W. Nicol Keith
    • 2
  • Marianne G. Rots
    • 1
  1. 1.Department of Pathology and Medical BiologyUniversity Medical Center GroningenGroningenThe Netherlands
  2. 2.Cancer Research UK Beatson LaboratoriesCentre for Oncology and Applied Pharmacology, University of GlasgowGlasgowUK

Personalised recommendations